Navigation Links
Novo Nordisk Appoints Alan C. Moses as Chief Medical Officer Worldwide
Date:1/9/2008

PRINCETON, N.J., Jan. 9 /PRNewswire-FirstCall/ -- Novo Nordisk, a healthcare company with an 84-year history of innovation and achievement in diabetes care, today announced the appointment of Alan C. Moses, M.D. as vice president, chief medical officer worldwide. Moses is currently the chief medical officer of Novo Nordisk Inc., the company's U.S. affiliate.

"Alan has the unique talent to integrate the science of discovery with new drug development -- a critical asset that will deepen Novo Nordisk's leadership position in changing diabetes," said Mads Krogsgaard Thomsen, executive vice president and chief science officer for Novo Nordisk A/S. "The broadening of Novo Nordisk's diabetes therapeutic portfolio with the development of liraglutide and other novel molecules in the pipeline, and the increasing importance of the U. S. to the Novo Nordisk business, requires a leader with clinical and research expertise to assume the role of chief medical officer."

In the newly expanded role, Moses will work closely with senior colleagues in Denmark to serve as the principle voice of clinical science for the company worldwide, providing clinical and medical affairs expertise.

"Novo Nordisk and the diabetes community in the U.S. have been fortunate to have Alan lead the efforts for the company in changing diabetes, and now, with his expanded responsibilities, the world will benefit from Alan's passion for research and advocacy for finding better ways for people to live with the disease," said Dr. Henrik Rasmussen, vice president of clinical development, medical and regulatory affairs, Novo Nordisk Inc.

Moses was formerly senior vice president and chief medical officer at the Joslin Diabetes Center and joined Novo Nordisk in April 2004 as associate vice president of medical affairs and since then has also assumed responsibility for clinical research in diabetes. Prior to joining Novo Nordisk, Dr. Moses spent 23 years at Harvard Medical School-affiliated institutions where he rose to the rank of Professor of Medicine. He has written more than 100 peer- reviewed articles on the treatment of diabetes and has been recognized both locally and nationally for his research in diabetes and growth factors.

Moses received a Bachelor of Science from Duke University and a Medical Doctorate from Washington University School of Medicine prior to training at Barnes Hospital in St. Louis, the National Institutes of Health in Bethesda, Md., and Tufts-New England Medical Center in Boston. He is board certified by the American Board of Internal Medicine and has a subspecialty certification in Endocrinology and Metabolism.

About Novo Nordisk

Novo Nordisk is a healthcare company with an 84-year history of innovation and achievement in diabetes care. The company has the broadest diabetes product portfolio in the industry, including the most advanced products within the area of insulin delivery systems. In addition to diabetes care, Novo Nordisk has a leading position within areas such as hemostasis management, growth hormone therapy, and hormone therapy for women. Novo Nordisk's business is driven by the Triple Bottom Line: a commitment to economic success, environmental soundness, and social responsibility to employees and customers. With headquarters in Denmark, Novo Nordisk employs more than 25,800 employees in 79 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For global information, visit novonordisk.com; for United States information, visit novonordisk-us.com.


'/>"/>
SOURCE Novo Nordisk
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Novo Nordisk Applauds Adoption of World Diabetes Day Resolutions by U.S. Congress
2. Novo Nordisk Inc. Announces Exclusive Agreement With Sciele Pharma, Inc. to Market Prandin(R)
3. Novo Nordisk Increased Operating Profit by 11% in the First Nine Months of 2007 Based on a 9% Sales Increase and an Improved Gross Margin
4. Drs. John Patton of Nektar, Igor Gonda of Aradigm, Tomas Landh of Novo Nordisk, Chris Rhodes of Amylin to Speak at iiBIGs Plenary Panel in Vegas
5. Ikaria Appoints Daniel Tasse as President and Chief Executive Officer
6. SRA Names Timothy J. Atkin Senior Vice President of Global Health Business; Appoints Mike Toner Global Health Unit Chief Financial Officer
7. Mersana Therapeutics Appoints C. Boyd Clarke Chairman of the Board of Directors
8. Chimerix Appoints Neil Frazer, M.B., Ch.B., FRCA, FFPM as Chief Medical Officer
9. Access Pharmaceuticals Appoints Jeffrey B. Davis as CEO
10. Seahorse Bioscience Appoints Former Molecular Devices Executive Dr. Joseph D. Keegan to Board of Directors
11. Kendle Appoints Former MHRA Head of Biologics as Principal Regulatory Affairs Consultant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... (PRWEB) , ... January 17, 2017 , ... ... completely re-engineered Drug Safety Technology Consortium™ (SafeTEC™), $3 million in investment towards 15+ ... these new tools and assays, and their applicability in drug safety assessment, for ...
(Date:1/17/2017)... MILPITAS, Calif. , Jan. 17, 2017 /PRNewswire/ ... today announced that it has initiated a global ... PTG-100, an oral peptide that targets alpha4beta7 integrin. ... design study is to evaluate the safety/tolerability and ... colitis patients with moderate to severe active disease. ...
(Date:1/16/2017)... , Jan. 16, 2017   Valentin A. ... Tracey, MD , president and CEO of The ... completed an analysis of how the nervous system regulates ... and develop bioelectronic medicine devices to treat ... Nature Neuroscience . The paper examines ...
(Date:1/14/2017)... ... January 14, 2017 , ... Seattle-based ... complete end-to-end genome assemblies to researchers around the globe. Long considered a ... in answering a wide range of scientific questions. The announcement was made ...
Breaking Biology Technology:
(Date:1/11/2017)... Jan. 11, 2017 Intoxalock, a leading ignition ... release of its patent-pending calibration device. With this new ... calibrations, securely upload data logs and process repairs at ... "Fighting drunk driving through the application of ... at large, but also for the customer who can ...
(Date:1/6/2017)... Colo. , Jan. 5, 2017  SomaLogic ... the "Digital Life Alliance" established by iCarbonX, the ... 2015 to build a "Global Digital Health Ecosystem ... on a combination of individual,s biological, behavioral and ... the agreement between the companies, SomaLogic will provide ...
(Date:1/4/2017)... , Jan. 4, 2017  CES 2017 – ... biometric sensor technology, today announced the launch of ... sensor systems, the highly-accurate biometric sensor modules that ... biometric technology, experience and expertise. The two new ... designed specifically for hearables, and Benchmark BW2.0, a ...
Breaking Biology News(10 mins):